TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06241846: A Multicenter, Open-Label, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With Metastatic Castration-Resistant Prostate Cancer

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$1,339,800

Rescue Site Savings

+$877,800

Unlock Full NCT06241846 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06241846 Rescue Dossier →